Articles On Imugene (ASX:IMU)

Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug c...

The Imugene Limited (ASX: IMU) share price is on course to end the week on a positive note. In morning trade, the clinical stage immuno-oncology company’s shares are up 8.5% to 38 cents. This latest gain means the Imugene share price is no...

Wall Street higher as US jobless claims plunged All the three major US benchmarks rose overnight, after US jobless claims fell to a new pandemic low. The Dow Jones rose by 0.38%, the S&P 500 by 0.52% to a fresh record high, while tech-f...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Shares in ASX biotech companies Anteotech Ltd (ASX: ADO), Imugene Ltd (ASX: IMU) and Little Green Pharma Ltd (ASX: LGP) have all posted exciting gains over the past 12 months. Let’s have a look at the share price performance and recent ne...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

ShareCafeHidden Gems Webinar Recap: RAC, IMU, AUA & BRN Catch up on the full webinar with presentations from Race Oncology (ASX:RAC), Imugene (ASX:IMU), Auderea (ASX:AUA) & Brainchip (ASX: BRN). Hidden Gems Webinar Recap: RAC, IM...

ShareCafeA clinical stage immuno-oncology company Imugene (ASX: IMU) – Hidden Gems Webinar. Presenter – Leslie Chong – CEO & Managing Director – Imugene is a clinical stage immuno-oncology company developing a range of new treatments t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Shares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unfortunately for investors, the Immugene share price has been on a heavy losing streak this week, falling 14% in the last 5 days. Imugene is...

The company believes new chief business officer Dr Monil Shah will make a valuable contribution to advance its immuno-oncology programs.

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The S&P/ASX 200 Index (ASX: XJO) has slipped today after a strong initial push into positive territory. At the time of writing, the ASX 200 is down 0.25% to 7,274.5 points. Let’s take a look at some of the ASX 200 shares that are being...

The S&P/ASX 200 Index (ASX: XJO) had a rather flat day today. The index finished up 0.15% at 7,292 points, well under its new all-time high of 7,315 points that we saw this morning. Let’s take a look at which ASX 200 shares were among...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

It has been a very volatile day for the S&P/ASX 200 Index (ASX: XJO) on Tuesday. However, in afternoon trade, things are looking positive and the index is up 0.2% to 7,294.8points. Four ASX shares that have failed to follow the market...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

The most notable directors trade over $100,000 in the last fortnight was a $4 million trade by Yaniv Meydan from Openpay (ASX:OPY). Meydan, who is based in Israel and whose family vehicle is one of Openpay’s largest shareholders, chipped in...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

By combining its cancer-killing virus with CAR T therapy, Imugene hopes to destroy solid tumours.

The Imugene Limited (ASX: IMU) share price has taken a large hit today. Shares were down over 30% earlier today, but have since recovered and are now trading 12% lower from yesterday’s close. Still, today’s dip isn’t too bad considering how...

ShareCafeAustralia…1 hour in… ASX200 up 14 ASX200 up 14 points (0.2%) to 7107.   AMP (+4.4%); is being sued by ASIC for “unconscionable behaviour” uncovered by the Hayne royal commission 3 years ago.  They were charging dead people.  AMP s...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

The company has enhanced its portfolio with a novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.

The Imugene Limited (ASX: IMU) share price has continued its positive run on Tuesday. At the time of writing, the immuno-oncology company’s shares are up over 13% to an all-time high of 46 cents. This latest gain means the Imugene share pr...

Biotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gains in May which has seen its share price rise by almost 500 per cent over the past 12 months. Each week, Stockhead recaps ASX stocks that are...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The Imugene Limited (ASX: IMU) share price hit an all-time high of 41 cents in intraday trade today, but with no news from the company since Tuesday, some market watchers are wondering why. At the time of writing, the Imugene share price...

Summary Extending gain for the third session, the ASX200 trades higher by 70 points or 0.51% at 7,059.30. Nuix led the pack with a 9% gain, while St Barbara nosedived over 10%, making it the top loser. Six of 11 sectors traded higher,...

A series of ASX announcements has attracted investors to the biotech sector today, lifting the share prices of some of its players. The buying frenzy has also lifted the broader health sector by as high as 1 per cent earlier today, but is c...

ShareCafeAustralia…1 hour in… ASX200 up 43 ASX200 up 43 points (0.6%) to 7067.   Boral (+0.6%); said it wants to buy US$450m in senior notes following the sale of its 50% share in its joint venture with USG Corp. Crown (-0.1%); the Royal C...

The Imugene Limited (ASX: IMU) share price is leaping higher today on the back of news the immuno-oncology company has entered into a licensing agreement. The agreement will see Imugene licensing the patents for a novel combination immunot...

The company has enhanced its portfolio with novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.

US and European stock markets down to start the week All major indices in US and Europe were down on Monday, after Covid cases spiked in some parts of the world. The Dow Jones was down 0.16%, S&P 500 fell 0.25%, and tech heavy NASDAQ dr...

This week’s Hot Money is more or less brought to you by the good folks at Mindax (ASX:MDX), with a nice cameo from Australia’s only listed football team. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relati...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred.

ShareCafeAustralia…1 hour in… ASX200 down 65 ASX200 down 65 points (0.9%) to 6952.   BHP (-1.8%); reported a 7% drop in Q Iron Ore shipments but still sees FY iron ore output near upper end of forecast. Challenger (-6.4%); still feeling un...

Imugene shares have hit a fresh all-time high this morning after the Sydney biotech said its HER-Vaxx cancer vaccine had achieved a clinical milestone in a phase 2 gastric cancer trial. The 36-patient trial met its secondary endpoint of imp...

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 0.35% to 6,970.7 points. Four ASX shares that are falling m...

ShareCafeAustralia…1 hour in… ASX200 down 11 ASX200 down 11 points (0.2%) to 6893   BHP (-0.2%); said the decision by its Brazilian joint venture with Vale SA to file for judicial reorganization is a last-resort response to legal actions f...

Singapore-based Asian American Medical Group (ASX:AAJ) was among the small cap names that ran red hot this week. Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trad...